In this episode, Jon Chee sits down with Sabrina Johnson, President and CEO of DARÉ Bioscience, to unpack the founding arc of a company built on a singular conviction: women's health is not a niche. Sabrina explains the choice to go public via reverse merger in 2017 to access capital in a space where only 1% of private healthcare investment funds women-specific conditions, and breaks down the groomed trail philosophy behind XACIATO, DARE to PLAY Sildenafil Cream, a pivotal Phase 3 contraceptive, and an ARPA-H-funded HPV treatment—all with 25 people and $75M+ in non-dilutive funding.
Podden och tillhörande omslagsbild på den här sidan tillhör
Excedr. Innehållet i podden är skapat av Excedr och inte av,
eller tillsammans med, Poddtoppen.